SciELO - Scientific Electronic Library Online

 
vol.15 número2Estudio de toxicidad por dosis única y tolerancia local de una vacuna antimeningocócica tipo B en ratas Sprague Dawley índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Vaccimonitor

versión impresa ISSN 1025-028Xversión On-line ISSN 1025-0298

Vaccimonitor v.15 n.2 Ciudad de la Habana mayo-ago. 2006

 

ARTICULO DE REVISION

Influenza. Vacunas clásicas y novedosas a las puertas de otra pandemia.

 

Influenza. Classic and novel vaccines on the verge of another pandemic.

 

Raiza Martínez, Nevis Amín, Alicia Aguilar, Frank Camacho, Ela María Pérez


Instituto Finlay. Centro de Investigación-Producción de Vacunas. Ave.27 No. 19805. La Lisa. A.P. 16017, C.P. 11600.
Ciudad de La Habana, Cuba. E-mail: rmartinez@finlay.edu.cu


RESUMEN

Los virus de la influenza A, además del hombre, infectan otros mamíferos y una gran variedad de especies de aves. Desde 1997 se sabe que cepas aviares son capaces de infectar al hombre provocando una enfermedad generalmente leve. El brote actual de gripe aviar H5N1 en humanos ha puesto en alerta a la comunidad científica internacional, no solo por su elevada mortalidad sino por su potencialidad en la generación de una nueva pandemia. Las autoridades sanitarias han puesto en marcha un amplio programa para la preparación ante esta contingencia, que abarca diferentes campos, desde el diagnóstico y la detección precoz de los brotes tanto en animales como en humanos, la caracterización sistemática de las cepas circulantes, el sacrificio de aves infectadas, la producción masiva de antivirales y por supuesto el desarrollo y producción a gran escala de vacunas eficaces. En este último tema se trabaja intensamente tanto en el mejoramiento de las vacunas ya existentes como en la búsqueda de alternativas basadas en tecnologías de nueva generación.

Palabras claves: Influenza, vacunas


ABSTRACT

Influenza A viruses infect humans and other mammalian and bird species. Since 1997, it has been known that some avian strains were able to infect humans, generally causing a mild disease.The present H5N1 avian influenza outbreak has led to a heightened level of awareness of the scientific and public health officials, not only because of its high mortality, but also because of its potential to trigger a new pandemic. In response to this emerging threat, the international sanitary authorities are developing a wide preparation program, which involving different measures such as the accurate diagnosis of animal and human outbreaks; systematic characterization of circulating strains; elimination of infected birds; mass production of antiviral drugs,and research,development and large scale production of efficacious vaccines. In the last aspect, great effort is being carried out for the improvement of classic vaccines and in the search for alternatives based on new technologies.

Keywords: Influenza, vaccines


Texto completo formato PDF

REFERENCIAS

1. Monto AS, Kiomerh F. The Tecumseh Study of respiratory illness. IX. Ocurrence of influenza in the community, 1966-1971. Am J Epidemiol 1975;102:553-63.
2. Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemic in the United States, 1970-78 Am J Public Health 1986;76:761-5.
3. Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982;4:2-44.
4. MMWR 2004; 53 (N0. RR-6)1-40.
5. Murphy BR WR. Orthomixoviruses. In: Fields KD, Howley PM, eds. Fields virology. Philadelphia, PA: Lippincott; 1996:1397-445.
6. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, Smith D, Rimmelzwaan GF, Olsen B, Osterhaus AD. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black headed gulls. J Virol 2005,79(5):2814-22.
7. Centers for Diseases Control (CDC), USA, 2005. Influenza Viruses. Types, Subtypes and Strains. November 2005. http://www.cdc.gov/flu/avian/gen-info/flu-viruses.htm .
8. Centers for Diseases Control (CDC), USA, 2004. Transmission of Influenza A viruses between animals and people. January 2004 http://www.cdc.gov/flu/about/fluviruses.htm .
9. Centers for Diseases Control (CDC), USA, 2006. Key Facts about Pandemic Influenza. January 2006. http://www.cdc.gov/flu/avian/gen-info/spread.htm .
12. WHO Avian influenza frequently asked questions. December 2005. http://www.who.int/csr/disease/avian_influenza/avian_faqs/en/index.html .
13. Centers for Diseases Control (CDC), USA, 2006. Avian influenza infection in humans. January 2006. http://www.cdc.gov/flu/avian/geninfo/avian-flu-humans.htm .
14. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, et al. Human infection with influenza H9N2. Lancet 1999; 354: 916-7.
15. Butt KM, Smith GJD, Chen H, Zhang LJ, LeungYHC, Xu KM, et al. Human infection with an avian H9N2 influenza in Hong Kong 2005. J Clin Microbiol 2005;43:5760-7.
16. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci USA 2004;101:1356-61.
17. Avian influenza virus A (H10N7) circulating among humans in Egypt. EID Weekly Updates 2004; 2:2.
18. WHO 2006. Avian influenza situation in Iraq. January 2006. http://www.who.int/csr/don/2006_1_30a/en/index.html .
19. WHO 2005. Respuesta a la amenaza de una pandemia de gripe aviar. Medidas estratégicas recomendadas. Septiembre 2005. http: // www.fao.org/ag/againfo/subjects/documents/ai/concmalaysia.pdf
21. WHO 2005. WHO laboratory guidelines for the collection of animal specimens for diagnosis of influenza. January 2005. http://www.who.int/csr/disease/avian_influenza/guidelines/animalspecimens/en/index.html .
22. Capua I, Terregino C, Catolli G, Mutinelli F, Rodríguez JF. Development of a DIVA- Differentiating infected from vaccinated animals-strategy using a vaccine containing a heterologous neuraminidase for the control of avian influenza. Avian Pathol 2003;32: 47-55.
23. Luschow D, Werner O, Mettenleiter TC, Fuchs W. Protection of chickens from lethal avian influenza A virus infection laryngotracheitis virus recombinants expressing the hemagglutinin (H5) gene. Vaccine 2001;19:4249-4259.
24. Swaine DE, Garcia M, Beck JR, Kinney N, Suárez DL. Proteccion against highly pathogenic H5 avian influenza viruses in chickens immunized with a recombinant fowlpox vaccine containing an H5 avian influenza hemagglutinin gene insert. Vaccine 2000;18:1088-1095.
25. WHO 2005. WHO laboratory guidelines for the collection of human specimens for diagnosis of influenza. January 2005. http://www.who.int/csr/disease/avian_influenza/guidelines/Guidance_sharing_viruses_specimens/en/index.html .
27. WHO 2005. WHO guidance on public health measures in countries experiencing their first outbreaks of H5N1 avian influenza. October 2005. http://www.who.int/entity/csr/disease/avian_influenza/guidelines/firstoutbreak/en/index.html .
28. WHO 2004. WHO interim guidelines on clinical management of human infected by influenza A (H5N1). March 2004. http://www.who.int/csr/disease/avian_influenza/guidelines/clinicalmana ge/en/index.html .
29. WHO 2005. WHO checklist for influenza pandemic preparedness planning. April 2005. http://www.who.int/entity/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005.
30. Centers for Diseases Control (CDC), USA, 2005. Vaccination Resources for Health Care Professionals. September 2005. http://www.cdc.gov/flu/professionals/vaccination/#recs.
31. Korsman S. Vaccines in Kamps BS, Hoffman C, Preiser W, eds. Influenza Report 2006. http://www.influenzareport.com/ir/vaccines.htm
32. Beare AS, Schild GC, Craig JW. Trials in man with live recombinants made from A/PR/8/34 (H0N1) and wild H3N2 influenza viruses. Lancet 1975;2:729-32.
33. Neumann G, Fujii K, Kino Y, Kawaoka Y. An improved reverse genetic system for influenza virus generation and its implications for vaccine production. Proc Natl Acad Sci USA 2005;102:16825-9.
34. Hilleman MR. Realities and enigmas of human vioral influenza pathogenesis, epidemiology and control. Vaccine 2002;20:3068-87.
35. Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997;175:1-6.
36. Couch RB, Keitel WA, Cate TR. Improvement of inactivated influenza virus vaccines. J Infect Dis 1997;176:Suppl 1.
37. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351:2286-94.
38. Cooper CL, Davis H, Cameron DW. Influenza vaccination with 1/10th the full dose. N Engl J Med 2004;351:2339-40.
39. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351:2295-301.
40. Langley JM, Halperin SA, McNeil S, et al. Safety and immunogenicity of a Proteosometrade mark-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine 2006;24(10):1601-1608.
41. Youngner JS, Treanor JJ, Betts RF, Whitaker-Dowling P. Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans. J Clin Microbiol 1994;32(3):750-4.
42. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barre syndrome following influenza vaccination. JAMA 2004; 292: 2478-81.
43. Belshe RB. The origins of pandemic influenza—lessons from the 1918 virus. N Engl J Med 2005;353:2209-11.
44. Musana KA, Yale SH, Mazza JJ, Reed KD. Practical considerations to influenza vaccination. Clin Med Res 2004;2:256-9.
45. WHO 2005. WHO intercountry-consultation. Influenza A/H5N1 in humans in Asia. Manila, Philippines, 6-7 May 2005. December 2005. http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_7_04.(pdf)
46. WHO 2005. Influenza vaccine. December 2005 at http://www.who.int/vaccines/en/influenza.shtml .
47. Centers for Disease Control (CDC) USA 2005. Interim Guideline: Planning for a Possible U.S. Influenza Vaccine Shortage, 2005-06. November 2005.
48. Fleming D. Influenza pandemics and avian flu. BMJ 2005; 331:1066-9.
49.Influenza Report by Bernard Sebastian kamps, Chistian Hoffman and Wolfgang Preiser (Editors).MedImmune Vaccines, Inc.FluMist 2005-2006 Formula.2005. http://www.fda.gov/cber/label/inflmed080505 LB.(pdf ).
50. Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy 2005;26:4-29.
51. Mitchell JA, Green TD, Brigh RA, Ross TM. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine. 2003;21(9-10):902-14.
52. Haan L, Verweij WR, Holtrop M, Brands R, van Scharrenburg GJ, Palache AM, Agsteribbe E, Wilschut J. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 2001; 19(20-22):2898-907.
53. Van Slooten ML, Hayon I, Babai I, Zakai-Rones Z, Wagner E, Storm G, Kedar E. Immunoadjuvant activity of interferon-gamma-liposomes coadministered with influenza vaccines. Biochim Biophys Acta. 2001; 1531(1-2):99-110.
54. Voeten JT, Rimmelzwaan GF, Nieuwkoop NJ, Lovgren-Bengtsson K, Osterhaus AD. Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8(+) cytotoxic T lymphocytes. Vaccine. 2000; 19(4-5):514-22.
55. Jones T, Cyr S, Allard S, Bellerose N, Lowell GH, Burt DS. Protollin: a novel adjuvant for intranasal vaccines. Vaccine 2004; 22(27-28):3691-7.
56. Galarza JM, Latham T, Cupo A. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 2005;18(2):365-72.
57. La Montagne JR, Fauci AS. Intradermal influenza vaccination—can less be more? N Engl J Med. 2004;351(22):2330-2.
58. Osterholm MT. Preparing for the next pandemic. N Engl J Med. 2005 May 5;352(18):1839-42.
59. http://www.inpharmatechnologist.com/news/ng.asp? n=63498&m=1IPEO31&c
60. Palese P, Zavala F, Muster T, Nussenzweig RS, garcia- Sastre A. Development of novel influenza virus vaccines and vectors. J Infect Dis 1997; 176: Suppl 1:S45-9.
61. Palese P, Garcia-Sastre A. New directions in vaccine research. J Clin Invest 2002; 109:1517-8.
62. Nicholson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine virus on Vero cells by reverse genetic: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005; 23 (22): 2943-52.
63. Newman G, Fujii K, Kino Y. An improved reverse genetic system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci USA 2005; 102: 16825-9.
64. Tang M, Harp JA, Wesley RD. Recombinant adenovirus encoding the HA gene from swine H3N2 influenza virus partially protects mice from challenge with heterologous virus: A/HK/1/68 (H3N2). Arch Virol. 2002; 147(11):2125-41.
65. Jeon SH, Ben-Yedidia T, Arnon R. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine 2002; 20(21-22):2772-80.
66. Kilbourne ED, Pokorny BA, Johansson B, Brett I, Milev Y, Matthews JT. Protection of mice with recombinant influenza virus neuraminidase. J Infect Dis 2004; 189(3):459-61.
67. de Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkiro A, Resch S, Fiers W. Universal influenza A vaccine: Optimization of M2-based constructs. Virology. 2005; 337: 149-161.
68. de Wit E, Munster VJ, Spronken MI, Bestebroer TM, Baas C, Beyer WE, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. J Virol 2005; 79(19):12401-7.
69. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259(5102):1745-9.
70. Ulmer JB, Fu TM, Deck RR, Friedman A, Guan L, DeWitt C, Liu X, Wang S, Liu MA, Donnelly JJ, Caulfield MJ. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 1998 ;72(7):5648-53.
71. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, Renshaw M, Sambhara S, Katz JM. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 2002;8(8):796-801.
72. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 2002; 83(Pt 8):1851-9.
73. Ljungberg K, Wahren B, Almqvist J, Hinkula J, Linde A, Winberg G. Effective construction of DNA vaccines against variable influenza genes by homologous recombination. Virology 2000;268(2):244-50

 

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons